ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in Milano, Lombardia

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma
Cancer
Pancreatic Cancer
Colorectal Cancer
Stomach Cancer
Esophageal Cancer
Prostatic Cancer

Adenocarcinoma trials near Milano, Lombardia, ITA:

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...

Active, not recruiting
Gastric Cancer, Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: Ramucirumab
Drug: Paclitaxel

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Milan, Italy and 155 other locations

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (TroFuse-015)

(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...

Enrolling
Gastroesophageal Cancer
Drug: Rescue medication
Drug: Supportive care measures

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Milan, Lombardia, Italy and 165 other locations

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PRISM-1)

The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitab...

Enrolling
Metastatic Pancreatic Ductal Adenocarcinoma
Drug: Gemcitabine
Drug: Nab-paclitaxel

Phase 3

Arcus Biosciences
Arcus Biosciences

Milano, Italy and 96 other locations

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302)

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.

Enrolling
PDAC - Pancreatic Ductal Adenocarcinoma
PDAC
Drug: 5-fluorouracil
Drug: leucovorin

Phase 3

Revolution Medicines
Revolution Medicines

Milan, Italy and 46 other locations

Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

esophageal adenocarcinoma.This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will b...

Enrolling
Gastroesophageal Adenocarcinoma
Esophageal Cancer
Drug: Levoleucovorin
Drug: Capecitabine

Phase 1, Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Milan, Lombardia, Italy and 39 other locations

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

the treatment of participants with advanced or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, o...

Enrolling
Gastroesophageal Adenocarcinoma
Esophageal Cancer
Biological: Ramucirumab
Biological: Sacituzumab Tirumotecan

Phase 1, Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Milan, Lombardia, Italy and 39 other locations

New

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection comp...

Begins enrollment in 1 month
Metastatic Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: 5-fluorouracil (5-FU)
Drug: Cisplatin

Phase 3

BeiGene
BeiGene

Milano, Italy and 86 other locations

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...

Active, not recruiting
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Drug: Domvanalimab
Drug: Zimberelimab

Phase 3

Arcus Biosciences
Arcus Biosciences

Milan, Italy and 210 other locations

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma...

Active, not recruiting
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
Drug: Trastuzumab
Drug: Paclitaxel

Phase 2, Phase 3

ALX Oncology

Milano, Italy and 83 other locations

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12)

after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...

Enrolling
Non-small Cell Lung Cancer
Drug: Pemetrexed
Drug: Rilvegostomig

Phase 3

AstraZeneca
AstraZeneca

Rozzano, Italy and 214 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems